EPZM Market Cap History
Below is a table of the EPZM market cap history going back to 5/31/2013:

Date EPZM Market Cap
5/31/2013615.83M
7/26/2013933.21M
10/18/20131.04B
2/21/2014984.79M
5/5/2014720.45M
8/8/20141.12B
10/31/2014906.35M
3/6/2015792.86M
4/24/2015832.75M
7/31/2015922.07M
10/30/2015545.90M
3/1/2016524.61M
5/2/2016610.57M
8/3/2016585.37M
10/28/2016530.80M
3/1/2017812.57M
5/1/20171.06B
8/1/2017701.60M
10/25/20171.11B
3/1/20181.23B
5/1/2018965.88M
7/30/2018854.89M
10/31/2018637.30M
2/19/2019964.74M
4/30/20191.13B
7/31/20191.21B
10/25/2019965.38M
2/19/20202.54B
4/30/20201.66B

Also see: EPZM Shares Outstanding History
and EPZM YTD Return
EPZM Historical Market Cap:
+15.44% CAGR
EPZM Historical Market Cap: +15.44% CAGR

Mouse over chart for data details
5/31/2013 ...4/30/2020
Epizyme is a biopharmaceutical company that is focused on rewriting treatment for people with cancer and other diseases. The U.S. Food and Drug Administration (FDA) granted approval of TAZVERIK™ (tazemetostat) for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase that Co. is developing. The FDA has also granted orphan drug designation to tazemetostat for the treatment of patients with follicular lymphoma, malignant rhabdoid tumors, soft tissue sarcoma, and mesothelioma. We show 29 historical shares outstanding datapoints in our EPZM shares outstanding history coverage, used to compute EPZM market cap on those dates.

Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing EPZM market cap history over the course of time is important for investors interested in comparing EPZM's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of EPZM versus a peer is one thing; comparing EPZM market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like EPZM can fluctuate over the course of history. With this page we aim to empower investors researching EPZM by allowing them to research the EPZM market cap history.
Quotes delayed 20 minutes
Get Free SEC filing alerts for EPZM:
EPZM SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: The Importance of Market Cap


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Epizyme (EPZM) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:

ESPR Market Cap History
ESRX Market Cap History
EVFM Market Cap History
EVHC Market Cap History
EVOK Market Cap History
EW Market Cap History
EXAS Market Cap History
EXEL Market Cap History
EYE Market Cap History
EYEG Market Cap History
More Healthcare companies »

 

EPZM Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2020, All Rights Reserved

Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.